News
RAPT
58.02
+0.03%
0.02
GSK completes acquisition of Rapt Therapeutics
TipRanks · 03/03 15:16
RAPT Therapeutics Completes Acquisition and Transitions to Private Ownership
TipRanks · 03/03 14:37
NASDAQ TRADE HALT <RAPT.O> TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Reuters · 03/03 00:50
Weekly Report: what happened at RAPT last week (0223-0227)?
Weekly Report · 03/02 10:30
GSK Expands Pipeline With $950 Million Pulmonary Hypertension Power Play
Benzinga · 02/25 12:22
Weekly Report: what happened at RAPT last week (0216-0220)?
Weekly Report · 02/23 10:30
GSK to buy Rapt Therapeutics for $58 a share
Reuters · 02/19 23:30
Weekly Report: what happened at RAPT last week (0209-0213)?
Weekly Report · 02/16 10:30
Weekly Report: what happened at RAPT last week (0202-0206)?
Weekly Report · 02/09 10:31
RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT
Barchart · 02/05 16:30
Clear Street says AbbVie move further validates Oruka Therapeutics’ strategy
TipRanks · 02/04 18:40
Weekly Report: what happened at RAPT last week (0126-0130)?
Weekly Report · 02/02 10:31
Weekly Report: what happened at RAPT last week (0119-0123)?
Weekly Report · 01/26 10:31
RAPT THERAPEUTICS <RAPT.O>: BARCLAYS RAISES TARGET PRICE TO $58 FROM $56
Reuters · 01/22 10:54
Rapt Therapeutics Price Target Announced at $58.00/Share by Barclays
Dow Jones · 01/21 19:31
Rapt Therapeutics Cut to Equal-Weight From Overweight by Barclays
Dow Jones · 01/21 19:31
Barclays Downgrades RAPT Therapeutics to Equal-Weight, Announces $58 Price Target
Benzinga · 01/21 19:20
Rapt Therapeutics downgraded to Equal Weight from Overweight at Barclays
TipRanks · 01/21 17:31
RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT
Barchart · 01/21 15:48
Rapt Therapeutics Cut to Market Perform From Outperform by Leerink Partners
Dow Jones · 01/21 13:07
More
Webull provides a variety of real-time RAPT stock news. You can receive the latest news about Rapt Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About RAPT
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.